biostudies-literatureBlanco-Martin TAxencia Galega de Innovación (GAIN)Centro de Investigación Biomédica en Red de Enfermedades InfecciosasMEC | Instituto de Salud Carlos IIIAxencia Galega de InnovaciónMEC | Instituto de Salud Carlos III (ISCIII)Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC)e0092424https://www.ebi.ac.uk/biostudies/studies/S-EPMC11539232biostudies-literatureUnknown68(11)We aimed to investigate the activity of and mechanisms of resistance to cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations in a nationwide collection of double-carbapenemase-producing Enterobacterales. In all, 57 clinical isolates co-producing two carbapenemases collected from Spanish hospitals during the period 2017-2022 were analyzed. Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Genetic drivers of resistance were analyzed by whoAntimicrobial agents and chemotherapyAssessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.PMC11539232JR23/00036CM21/00076PI23/00851PI22/01212CM23/00104IN607D 2021/12IN607A 2016/22JR21/00026IN606A 2023/023CB21/13/00012CB21/13/00055PI21/00704PI20/01212PI20/00686CB21/13/00095FI23/00074IN606B 2022/009CM23/00095PMP22/00092Aja-Macaya PAracil BOteo-Iglesias JGonzalez-Pinto LPascual ASanchez-Pena LLopez-Hernandez IRodriguez-Pallares SArca-Suarez JAlonso-Garcia IBlanco-Martin TPerez-Vazquez MBeceiro ABou GLopez-Cerero LGEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)Outeda-Garcia MVazquez-Ucha JCfalseAssessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.We aimed to investigate the activity of and mechanisms of resistance to cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations in a nationwide collection of double-carbapenemase-producing Enterobacterales. In all, 57 clinical isolates co-producing two carbapenemases collected from Spanish hospitals during the period 2017-2022 were analyzed. Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Genetic drivers of resistance were analyzed by who2024-01-01T00:00:00Z2024 Nov2026-06-01T17:57:07.866Z2025-07-14T03:02:42.221ZS-EPMC115392323938227410.1128/aac.00924-24